Literature DB >> 3138435

Establishment of a model to evaluate inhibition of bone resorption induced by human prostate cancer cells in nude mice.

R Nemoto1, S Kanoh, K Koiso, M Harada.   

Abstract

A model system of human prostate carcinoma in nude mice for searching out a method to protect the bone from cancer cells is described, in which the transplanted human prostate cancer cells were inoculated subcutaneously over the calvaria in nude mice after the periosteum wa disrupted. The tumor induced osteolysis associated with osteoclast proliferation accompanied with reactive new bone formation. This osteolysis was evaluated by measuring the increased area of bone resorption by its reduced opacity to X-ray, and histology. Etidronate disodium, a diphosphonate derivative, at a dose of three mg./kg. and 10 mg./kg. s.c. protected the bone by decreasing the extent of osteolysis as judged by the above criteria. This inhibition was obtained with no apparent effect on the growth of the tumor. These results are discussed in light of recent clinical work, showing that this animal model is a useful tool to test the effect of new drugs against osteolysis of cancer as well as to study the biology of local interaction between bone and cancer cell.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3138435     DOI: 10.1016/s0022-5347(17)41848-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Authors:  J Zhang; J Dai; Y Qi; D L Lin; P Smith; C Strayhorn; A Mizokami; Z Fu; J Westman; E T Keller
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  New bone formation and cancer implants; relationship to tumour proliferative activity.

Authors:  R Nemoto
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

3.  Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice.

Authors:  R Nemoto; Y Nishijima; K Uchida; K Koiso
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.